Jens Rueter, M.D.
Chief Medical Officer, JAX; Medical Director, MCGI
Rueter is the Chief Medical Officer of JAX, Medical Director of MCGI, and Associate Director for Translational Education at JAX Cancer Center. Rueter provides direction, leadership, and strategy for JAX’s translational and clinical research activities and clinically-oriented operations.
Jens Rueter, M.D. is the Chief Medical Officer of The Jackson Laboratory and Medical Director for the Maine Cancer Genomics Initiative. Rueter is a practicing hematologist/oncologist in Maine and has served as Medical Director for MCGI since its inception in 2016. In 2021, Rueter was named JAX’s first CMO and serves as the institution’s principal medical advisor.
Rueter came to JAX from Eastern Maine Medical Center Cancer Care (EMMC) in Brewer, Maine, where he was Medical Director for EMMC’s Translational Oncology Program and the EMMC Biobank. He has been on staff at Northern Light Eastern Maine Medical Center since 2010, and a member of the JAX adjunct faculty since 2012. Prior to joining JAX, Rueter collaborated with several JAX investigators and technicians on developing new approaches to treating cancers while advancing translational research at EMMC. After graduating from medical school in Berlin, Germany, Rueter completed his residency in internal medicine at Tulane University and fellowship training in hematology/oncology at the University of Pennsylvania.
-
ArticleMay 01, 2024Cancer patients gain important benefits from genome-matched treatments
A study from MCGI indicates that Maine cancer patients experienced better outcomes following genomic tumor testing to guide targeted therapy strategies; but a gap between testing and clinical delivery still exists. -
Featured ArticleNovember 07, 2023The state of biomedicine presented at the Biomedical Innovation and Technology Conference
The current state of biomedicine and its potential for the future in Maine and beyond as presented in the inaugural Biomedical Innovation and Technology (BIT) Conference. -
Featured ArticleJune 14, 2023Bringing precision cancer care to Maine patients
Examining how MCGI has dramatically improved cancer care in Maine, from its inception in 2016 to today. -
Press ReleaseOctober 24, 2022JAX participates in A Day of Hope for Maines cancer fighters
Eight team members who make up JAX's MCGI recently attended MaineGeneral's annual Day of Hope Event at the Augusta Civic Center.
-
Press ReleaseDecember 19, 2023JAX's 2023 achievements
JAX is celebrating important research breakthroughs, new faculty and leadership appointments, and crucial advancements in legislation. -
Featured ArticleJuly 10, 2023Rueter and Rosenthal to headline 2023 Forum for Discovery
Harnessing genetics to understand personalized cancer care and regenerative medicine. -
Blog PostJanuary 09, 2023MCGI: Meet the team
Learn more about the JAX MCGI team, including roles and fun facts. -
Featured ArticleJune 28, 2022JAX Genomic Medicine is increasing the precision of brain cancer diagnoses
The new technique of methylome profiling, now available from The Jackson Laboratory, provides more precise tumor classification for cancers of the central nervous system (CNS).